Prevalence of Human papillomavirus (HPV) Infection and Genotypes in Thai Women with Normal Cervical Cytology
Keywords:
human papillomavirus, prevalence, HPV typeAbstract
Cervical cancer, caused by Human Papillomaviruses (HPV) infection, is the second most common cancer in Thai women. HPV vaccination is an effective prevention measure, however, information on HPV infection prevalence and circulating HPV types is limited. We, therefore, aimed to survey HPV prevalence in Thai women with normal cytology at Nakornping Hospital, Khon Kaen Hospital, Lopburi cancer Hospital and Songkla Hospital located in 4 regions of the country. A total of 487 women attending a cervical screening program at each hospital were recruited into the survey during 2014-2016. All were screened for cervical cancer by Liquid-based Pap test and for HPV DNA by Real-time Polymerase Chain Reaction (Real-time PCR) technic. It was found that 14 of 487 (2.9%) women showed abnormal cytology while 473 (97.1%) had normal cytology results. Real-time PCR results demonstrated HPV infections in 98 of 473 cases (20.7%). HPV types with high and low risks of infection were found at the percentages of 12.1 and 5.5, respectively. Additionally, mixed infections were also found at the percentage of 3.4. The common high risk types were HPV 16 (17.5%) followed by HPV 66 (11.3%), HPV 52 (10.0%) and HPV 53 (10.0%), while the common low risk types were HPV 42 (20.8%), HPV 6 (15%), HPV 40 (15%) and HPV 54 (13%). In our survey, most HPV-infected women were less than 30 years of age. The infection was statistically significant lower in higher age groups. Moreover, we found that more than one sexual partner as well as low income were major risk factors leading to HPV infections. Our data could be useful for further development of new HPV vaccines suitable for Thai women.
References
National Cancer Institute, Ministry of Public Health (Thailand). Cancer in Thailand Vol. IX, 2013-2015. [Online]. Available from: URL: https://www.nci.go.th/th/File_download/Nci%20Cancer%20Registry/Cancer%20in%20Thailand%20IX_(Unpublished%20Edition)03.pdf.
Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gomez D, et al. ICO/IARC In-formation Center on HPV and Cancer. Human papillomavirus and related diseases in the world. Summary report 27 July 2017. [Online]. Available from: URL: https://hpvcentre.net/statistics/reports/XWX.pdf.
Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin virol 2005; 32(Suppl 1): S16-S24.
Wentzensen N, Schiffman M, Dunn ST, Zuna RE, Walker J, Allen RA, et al. Grading the se-verity of cervical neoplasia based on combined histopathology, cytopathology, and HPV geno-type distribution among 1700 women referred to colposcopy in Oklahoma. Int J Cancer 2009; 124(4): 964-9.
Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297(8): 813-9.
Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer-burden and as-sessment of; causality. J Natl Cancer Inst Monogr 2003; (31): 3-13.
Braaten KP, Laufer MR. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol 2008; 1(1): 2-10.
Signorelli C, Odone A, Ciorba V, Cella P, Audicio RA, Lombardi A, et al. Human papilloma-virus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. Ep-idemiol Infect 2017; 145(10): 1962-82.
Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the international agency for research on cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 991-8.
de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et al. Worldwide preva-lence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7(7): 453-9.
Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202(12): 1789-99.
Allan B, Marais DJ, Hoffman M, Shapiro S, Williamson AL. Cervical human papillomavirus (HPV) infection in South African women: implications for HPV screening and vaccine strate-gies. J Clin Microbiol 2008; 46(2): 740-2.
Pista A, de Oleveira CF, Cunha MJ, Paixao MT, Real O. Prevalence of human papillomavirus infection in women in Portugal: the CLEOPATRE Portugal study. Int J Gynecol Cancer 2011; 21(6): 1150-8.
Zhao FH, Zhu FC, Chen W, Li J, Hu YM, Hong Y, et al. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial. Int J Cancer 2014; 135: 2604-11.
Kantathavorn N, Mahidol C, Sritana N, Sricharunrat T, Phoolcharoen N, Auewarakul C, et al. Genotypic distribution of human papillomavirus (HPV) and cervical cytology findings in 5906 Thai women undergoing cervical cancer screening programs. Infect Agent Cancer 2015; 10: 7.
Chopjitt P, Ekalaksananan T, Pientong C, Kongyingyoes B, Kleebkaow P, Charoensri N. Prevalence of human papillomavirus type 16 and its variants in abnormal squamous cervical cells in Northeast Thailand. Int J Infect Dis 2009; 13(2): 212-9.
Swangvaree SS, Kongkaew P, Rugsuj P, Saruk O. Prevalence of high-risk human papillomavirus infection and cytologic result in Thailand. Asian Pac J Cancer Prev 2010; 11(6): 1465-8.
Chansaenroj J, Lurchachaiwong W, Termrungruanglert W, Tresukosol D, Niruthisard S, Trivi-jitsilp P, et al. Prevalence and genotypes of human papillomavirus among Thai women. Asian Pac J Cancer Prev 2010; 11(1): 117-22.
Marks MA, Gupta S, Liaw KL, Tadesse A, Kim E, Phongnarisorn C, et al. Prevalence and correlates of HPV among women attending family-planning clinics in Thailand. BMC Infect Dis 2015; 15: 159. (11 p.).
Anderson L, O’Rorke M, Jamison J, Wilson R, Gavin A. Prevalence of human papillomavirus in women attending cervical screening in the UK and Ireland: new data from northern Ireland and a systematic review and meta-analysis. J Med Virol 2013; 85(2): 295-308.
Agarossi A, Ferrazzi E, Parazzini F, Perno CF, Ghisoni L. Prevalence and type distribution of high-risk human papillomavirus infection in women undergoing voluntary cervical cancer screening in Italy. J Med Virol 2009; 81(3): 529-35.
Lurchachaiwong W, Junyangdikul P, Payungporn S, Sampatanukul P, Chansaenroj J, Tresuko-sol D, et al. Human papillomvirus genotypes among infected Thai women with different cyto-logical findings by analysis of E1 genes. New Microbiol 2011; 34(2):147-56.
Casalegno JS, Benchaib M, Le Bail Carval K, Piaton E, Mathevet P, Mekki Y. Human papillomavirus genotype distribution among French women with and without cervical abnormalities. Int J Gynecol Obstet 2011; 114(2): 116-9.
Ralston HE, Li Z, McGlennen RC, Hellerstedt WL, Downs LS. Type-specific prevalence and persistence of human papillomavirus in women in the United States who are referred for typing as a component of cervical cancer screening. Am J Obstet Gynecol 2009; 200(3): 245.e1-7.
